

December 10, 2024

BrightPath Presented the Preclinical Data of BP1223 in Blood Cancer at ASH 2024

Tokyo, Japan - December 10, 2024/ -- BrightPath Biotherapeutics (TSE Growth 4954, "BrightPath"), a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutics, today announced that BrightPath had presented preclinical data on T-cell Engager BP1223 at the 66th American Society of Hematology Annual Meeting (ASH 2024, December 7-10, San Diego).

BP1223 is a T cell engager that targets CD39, antigens often expressed on the surface of hematologic cancer cells including acute myeloid leukemia (AML), while binding CD3 expressed on T cells, activating and redirecting T cells to eliminate cancer cells.

While a combination therapy of venetoclax and azacitidine has lately become a standard therapy for AML patients with improved responses, there remains a significant unmet need to improve its overall survival. It is considered that AML blasts cause relapse by acquiring resistance to the drugs.

"We found that CD39 expression in AML blasts correlated with venetoclax resistance. Consequently, targeting CD39 is expected to enable the elimination of AML blasts that are not effectively removed by venetoclax-based therapies", commented Kenichi Nagai, CEO of BrightPath.

BP1223 demonstrated T cell-mediated cytotoxicity against AML blasts derived from AML patient samples, both as a monotherapy and, more notably, in combination with venetoclax. Furthermore, BP1223 achieved complete tumor regression as a monotherapy in an AML cell line-derived xenograft model. These data indicate that BP1223 represents a novel therapeutic approach for AML, including CD39-positive and chemotherapy-resistant cases.

More detailed results are available on the websites of [BrightPath](#).

About BrightPath:

BrightPath is a clinical stage biopharmaceutical company focused on the development of novel cancer therapeutics to transform cancer treatment for refractory or progressive cancers that cannot be treated with conventional standard therapies. BrightPath is actively involved in developing cell therapies currently and immunomodulatory antibodies.

For more information, visit www.brightpathbio.com

Investor and Media Contact:

irpr@brightpathbio.com

www.brightpathbio.com